PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 6

Complete if Known	
Application Number	09/307,223
Filing Date	May 7, 1999
First Named Inventor	Judith A. Varner
Group Art Unit	NYA
Examiner Name	NYA
Attorney Docket Number	6627-PA11

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	A1	US5753230		Brooks et al	05-19-98
	A2	US5766591		Brooks et al.	06-16-98
	A3	US5627263		Rouslahti et al.	05-06-97
	A4	US5855866		Thorpe et al	01-05-99

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4] (if known)	Kind Code[5]	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T[6]
	B1		WO95/14714		LA JOLLA CANCER RESEARCH FOUNDATION	06-01-95	
	B2		WO97/10507		LA JOLLA CANCER RESEARCH FOUNDATION	03-20-97	
	B3		WO98/10795		LA JOLLA CANCER RESEARCH FOUNDATION	03-19-98	
	B4		WO99/13329		LA JOLLA CANCER RESEARCH FOUNDATION	03-18-99	
	B5		EP0906919A2		LA JOLLA CANCER RESEARCH FOUNDATION	04-07-99	

Examiner Signature [signature] Date Considered 8/21/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents.
[5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 6

Complete if Known	
Application Number	09/307,223
Filing Date	May 7, 1999
First Named Inventor	Judith A. Varner
Group Art Unit	NYA
Examiner Name	NYA
Attorney Docket Number	6627-PA11

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C1	AOTA, S., NOMIZU, M., and Yamada, K.M. 1994. The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J. Biol. Chem. 269: 24755-24761.	
	C2	ARAP W et al. 1997. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380.	
	C3	BADER, B.L. et al. 1998. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins. Cell 95: 507-519.	
	C4	BLOCH, W. et al. 1997. β1 integrin is essential for teratoma growth and angiogenesis. J. Cell Biol. 139: 265-278.	
	C5	BLYSTONE, S.D. et al. 1994. Integrin αvβ3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor α5β1. J. Cell Biol. 127: 1129-1137.	
	C6	BROOKS, P.C. et al. 1994a. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571.	
	C7	BROOKS, P.C. et al. 1994b. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164.	
	C8	BROOKS, P.C., et al. 1995. Anti-integrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96: 1815-1822.	

Examiner		Date Considered	8/21/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 6

Complete if Known	
Application Number	09/307,223
Filing Date	May 7, 1999
First Named Inventor	Judith A. Varner
Group Art Unit	NYA
Examiner Name	NYA
Attorney Docket Number	6627-PA11

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C9	CARRON, C.P. et al.1998. A peptidomimetic antagonist of the integrin αvβ3_inhibits Leydig cell tumor growth and development of hypercalcemia of malignancy. Cancer Res. 58: 1930-1955.	
	C10	CASTELLANI, P. et al. 1994. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59: 612-618.	
	C11	CHARO, IF et al. 1990. The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin. J. Cell Biol. 111: 2795-800.	
	C12	CHRISTOFIDOU-SOLOMIDOU, M. et al. 1997. Expression and function of endothelial cell αv integrin receptors in wound-induced human angiogenesis in human skin/SCID mice chimeras. Am. J. Path. 151: 975-983.	
	C13	CLARK, R.A.F. et al. 1982. Blood vessel fibronectin increases in conjunction with endothelial cell proliferation and capillary ingrowth during wound healing. J. Invest. Dermatol. 79: 269-276.	
	C14	CLARK, R.A.F. et al. 1996. Transient functional expression of αvβ3 on vascular cells during wound repair. Am. J. Path. 148: 1407-1421.	
	C15	COLLO, G. and Pepper, M.S. 1999. Endothelial cell integrin α5β1_expression is modulated by cytokines and during migration in vitro. J. Cell Sci. 112: 569-578.	
	C16	DRAKE, C.J. et al. 1992. Antibodies to beta 1-integrins cause alterations of aortic vasculogenesis, in vivo. Dev. Dyn. 193: 83-91.	
	C17	DRAKE, C.J. et al. 1995. An antagonist of integrin αvβ3 prevents maturation of blood vessels during embryonic neovascularization. J. Cell Science 108: 2655-2661.	
	C18	FRIEDLANDER, M. et al. 1995. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270:1500-1502.	
Examiner		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. [1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	09/307,223
Filing Date	May 7, 1999
First Named Inventor	Judith A. Varner
Group Art Unit	NYA
Examiner Name	NYA
Attorney Docket Number	6627-PA11

Sheet 4 of 6

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C19	FRIEDLANDER M. et al. 1996. Involvement of integrin αvβ3 and αvβ5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. 93: 9764-9769.	
	C20	GEORGE, E. L., et al. 1993. Defects in mesodermal migration and vascular development in fibronectin-deficient mice. Development 119: 1079-1091.	
	C21	GOH, K. L. et al. 1997. Mesodermal defects and cranial neural crest apoptosis in α5 integrin-null embryos. Development 124: 4309-4319.	
	C22	LAN, N. et al. 1998. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J. Cell Sci.111: 3621-3631.	
	C23	KACZMAREK, J. et al. 1994. Distribution of oncofetal fibronectin isoforms in normal hyperplastic and neoplastic human breast tissues. Int. J. Cancer 58: 11-16.	
	C24	KOIVUNEN, E. et al. 1993. Selection of peptides binding to the α5β1 integrin from a phage display library. J. Biol. Chem. 268: 20205-20210.	
	C25	KOIVUNEN, E., Wang, B., Ruoslahti, E. 1994. Isolation of a highly specific ligand for the α5β1 integrin from a phage display library. J. Cell Biol. 124: 373-380.	
	C26	MAGNUSSON, M.K. and Mosher, D.F. 1998. Fibronectin: Structure, assemby, and cardiovascular implications. Arterioscler. Thromb. Vasc. Biol. 18: 1363-1370.	
	C27	NERI, D., Camemolla, B., Nissim, A., Blaza, E., Leprini, A., Querze,' G., Pina, A., Tarli, L., Halin, C., Neri, P., Zardi, L. Winter, G. 1997. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform, Nature Biotech. 15: 1271-1275.	
	C28	PIERSCHBACHER, M.D., Hayman, EG; and Ruoslahti, E. 1981. Location of the cell-attachment site in fibronectin with monoclonal antibodies and proteolytic fragments of the molecule. Cell 26: 259-67.	

Examiner		Date Considered	8/24/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 6

Complete if Known	
Application Number	09/307,223
Filing Date	May 7, 1999
First Named Inventor	Judith A. Varner
Group Art Unit	NYA
Examiner Name	NYA
Attorney Docket Number	6627-PA11

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C29	PYTELA, R. et al. 1985. Identification and isolation of a 140 kD cell surface glycoprotein with properties expected of a fibronectin receptor. Cell 40: 191-98.	
	C30	RUOSLAHTI, E. et al. 1981. Alignment of biologically active domains in the fibronectin molecule. J. Biol. Chem. 256:7277-81.	
	C31	SECHLER, J. L. and Schwartzbauer, J.E. 1998 Control of cell cycle progression by fibronectin matrix architecture. J. Biol. Chem. 273: 25533-25536.	
	C32	SENGER, D.R. et al. 1996. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphav beta3 integrin, osteopontin, and thrombin. Am. J. Pathol. 149:1-7.	
	C33	SENGER, D. R. et al. 1997. Angiogenesis promoted by vascular endothelial growth factors: Regulation through α1β1_and α2β1 integrins. Proc. Nat'l Acad. Sci. USA 94: 13612-13617.	
	C34	SIMON, K.O. et al. 1997. The αvβ3 integrin regulates α5β1-mediated cell migration toward fibronectin. J. Biol. Chem. 272: 29380-29389.	
	C35	STROMBLAD S., et al. 1996. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 98: 426-433.	
	C36	STROMBLAD, S. and Cheresh, D. A. 1996. Integrins, angiogenesis and vascular cell survival. Chemistry and Biology 3: 881-885.	
	C37	SUEHIRO,K., GAILIT, J. and Plow, E.F. 1997. Fibrinogen is a ligand for integrin α5β1 on endothelial cells. J. Biol. Chem. 272: 5360-5366.	
	C38	VARNER, J.A. 1997. The role of vascular cell integrin αvβ3 and αvβ5 in angiogenesis., Regulation of Angiogenesis (ed. by I.D. Goldberg & E.M. Rosen Birkhauser Verlag, Basel/Switzerland) Exs. 79: 361-390.	
	C39	VARNER, J.A. et al. 1995. Integrin α5β1 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol. Biol. Cell 6: 725-740.	
Examiner			Date Considered 8/21/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	09/307,223
Filing Date	May 7, 1999
First Named Inventor	Judith A. Varner
Group Art Unit	NYA
Examiner Name	NYA
Attorney Docket Number	6627-PA11

Sheet 6 of 6

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
PJM	C40	YANG, J.T., et al. 1993. Embryonic mesodermal defects in α5 integrin-deficient mice. Development 119: 1093-1105.	

Examiner		Date Considered	8/21/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/307,223
				Filing Date	May 7, 1999
				First Named Inventor	Varner, Judith A.
				Art Unit	1642
(use as many sheets as necessary)				Examiner Name	S. Ungar
Sheet	1	of	1	Attorney Docket Number	021935-000110US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	BC	Guo, Neng-hua, et al., "Thrombospondin 1 and Type I Repeat Peptides of Thrombospondin 1 Specifically Induce Apoptosis of Endothelial Cells", *Cancer Res.*, (1997), 57: 1735-1742	
	BD	Kim, Semi, et al., "Regulation of Angiogenesis *in Vivo* by Ligation of Integrin $\alpha 5\beta 1$ with the Central Cell-Binding Domain of Fibronectin", *American Journal of Pathology*, (2000), 156(4): 1345-1362	
	BE	Ruoslahti, Erkki, "Integrin Signaling and Matrix Assembly", *Tumor Biology*, (1996) 17(2):117-124	
	BF	Scott, Glynis, et al, "Fibronectin Suppresses Apoptosis in Normal Human Melanocytes Through an Integrin-Dependent Mechanism", *J. Invest. Dermatol.*, (1997) 108:147-153	
	BG	Yano, Yoshiko, et al, "Cyclic Strain Induces Reorganization of Integrin $\alpha_5\beta_1$ and $\alpha_2\beta_1$ in Human Vein Endothelial Cells", *Journal of Cellular Biochemistry*, (1997) 64(3):505-513	
	BH	Zhang, Zhuohua, et al. "The $\alpha 5\beta 1$ integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression", *Proc. Natl. Acad. Sci USA*, (1995) 92:6161-6165	
	BI		
	BJ		
	BK		
	BL		
	BM		

Examiner Signature		Date Considered	8/21/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

OIPE JC37 AUG 11 2005 PATENT & TRADEMARK OFFICE

PTO/SB/08A (08-03)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete If Known	
Application Number	10/685,665
Filing Date	October 14, 2003
First Named Inventor	Varner, Judith A.
Art Unit	1645
Examiner Name	S. Ungar
Attorney Docket Number	021935-000130US

U.S. PATENT DOCUMENTS+

Examiner Initials*	Cite No.[1]	Document Number: Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PR	AA	US-5,677,181	10/14/1997	Parish	
PR	AB	US-5,874,081	02/23/1999	Parish	
PR	AC	US-6,123,941	09/26/2000	Bissell	
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			
	AL	US-			
	AM	US-			
	AN	US-			
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			
	AS	US-			
	AT	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]	Number[4]	Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	AU							☐
	AV							☐
	AW							☐
	AX							☐
	AY							☐
	AZ							☐
	BA							☐
	BB							☐

Examiner Signature	/Peter Reddig/	Date Considered	08/21/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/685,665
				Filing Date	October 14, 2003
				First Named Inventor	Varner, Judith A.
				Art Unit	1645
(use as many sheets as necessary)				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	021935-000130US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
PR	BC	CONFORTI, et al. "Human Endothelial Cells Express Integrin Receptors on the Luminal Aspect of their Membrane", *Blood* (1992) 80(2):437-446	
	BD		
	BE		
	BF		
	BG		
	BH		
	BI		
	BJ		
	BK		
	BL		
	BM		

Examiner Signature	/Peter Reddig/	Date Considered	08/21/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.